secwatch.observer — SEC 8-K summary
======================================

Issuer:     LB PHARMACEUTICALS INC (LBRX)
CIK:        0001691082
Form:       8-K
Filed at:   2026-08-11T12:05:45+00:00
Accession:  0001193125-26-343479
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LB Pharma Q2 net loss $51.6M, cash $327.8M, NOVA-2 readout accelerated to H1 2027
--------------------------------------------------------------------------------

- Q2 2026 net loss $51.6M vs $4.9M; R&D expenses $44.1M vs $2.4M.
- Cash and marketable securities $327.8M at 6/30/26, plus $150M July private placement; runway beyond Q2 2029.
- Pivotal Phase 3 NOVA-2 topline readout accelerated to H1 2027; pre-NDA meeting planned H2 2027.
- Phase 2 bipolar depression (ILLUMINATE-1) data expected Q1 2028; MDD adjunctive trial starts early 2027.
- Appointed Christopher Zergebel as SVP Clinical Operations in June 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1691082/000119312526343479/0001193125-26-343479-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1691082/000119312526343479/d303033d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-343479

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer